PMID: 9432044Jan 31, 1998Paper

Incidence of AML1/ETO fusion transcripts in patients entered into the MRC AML trials. MRC Adult Leukaemia Working Party

British Journal of Haematology
S E LangabeerD Linch

Abstract

Acute myeloid leukaemia (AML) with the t(8;21)(q22;q22) is deemed to be a 'good-risk' disease. 396 patients with AML at diagnosis were screened for the presence of t(8;21) and AML1/ETO fusion transcripts by cytogenetic and RT-PCR techniques respectively. 32 cases of t(8;21) were detected, all of which were also PCR positive. A further 19 cases were detected at the molecular level, predominantly but not exclusively in M1 and M2 FAB types. Approximately 12% of all new cases of AML are estimated to have AML1/ETO fusion transcripts and it is suggested that molecular screening should be performed in all cases with the possible exception of the M3 FAB type.

Citations

Jan 21, 2000·Hematological Oncology·S K MaL C Chan
Nov 19, 2003·Cancer Genetics and Cytogenetics·Masahiro OnozawaIsao Maekawa
Mar 11, 2004·Blood Reviews·Krzysztof MrózekClara D Bloomfield
Feb 13, 2001·British Journal of Haematology·S E LangabeerUNKNOWN MRC Adult Leukaemia Working Party
Oct 28, 2008·Proceedings of the National Academy of Sciences of the United States of America·Eun-Young AhnDong-Er Zhang
Dec 1, 2004·Proceedings of the National Academy of Sciences of the United States of America·Ming YanDong-Er Zhang
Jul 26, 2003·Proceedings of the National Academy of Sciences of the United States of America·Jay L GrisolanoMichael H Tomasson
Mar 20, 2003·Cancer Investigation·Joäelle MichaudRobert Escher
Oct 24, 2006·British Journal of Haematology·UNKNOWN British Committee for Standards in HaematologyG Jackson
Oct 21, 2005·Critical Reviews in Oncology/hematology·Björn SteffenHubert Serve
May 4, 2002·Best Practice & Research. Clinical Haematology·J A Liu Yin
May 23, 2003·The Korean Journal of Internal Medicine·Eun Kyung ChoJae Hoon Lee
Jul 14, 2010·BMC Gastroenterology·Yefei RongDayong Jin
Oct 20, 2001·Best Practice & Research. Clinical Haematology·D Grimwade
May 18, 2001·Best Practice & Research. Clinical Haematology·D M Swirsky, S J Richards
Sep 26, 2006·Best Practice & Research. Clinical Haematology·Dietger NiederwieserHaifa Al-Ali
Jun 13, 2002·Reviews in Clinical and Experimental Hematology·Alan K Burnett
May 29, 2002·Oncogene·Joseph M ScanduraStephen D Nimer
Mar 28, 2003·Genes, Chromosomes & Cancer·Jennifer SnaddonJude Fitzgibbon
Dec 25, 2007·The Korean journal of laboratory medicine·Hyunjung KimHee Je Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.